|
Hosted by
Sponsored
by
|
Dear Visitor,
Our confirmed
start-up companies are listed below.
Matt Noah,
Conference Chairman,
matt@mnvcc.com
|
Start-Ups Selected to Present |
|
 |
Kevin Mayo, CSO
3701 Shoreline Drive, Suite 202-C
Wayzata, MN 55391
952-471-3336
actipep@aol.com |
|
ActiPep
Biotechnology, Inc. is an early stage drug discovery company
focused on developing novel cancer and anti-bacterial
therapeutics . We have licensed a family of small peptide based
tumor targeting agents, a family of potent broad-spectrum
anti-bacterial agents, two EGFR/erbB-related protein drug
candidates known to kill cancer cells in tissue cultures. One
of the tumor targeting agents (AngiNEXTM) is ready
for phase I trials in Europe, two clinical sites have been
chosen and protocol written. The anit-bacterial agent ProSEPTM
has successfully passed the in-vitro stage and is ready for
pre-clinical testing as soon as sufficient funding is received.
The EGFR/erbB related peptides are ready for in-vitro testing
against various cancer cell lines. In addition, we have
arranged to license a novel peptide that mimics anti-EGFR
monoclonal antibody (“MAb”) and plan pre-clinical studies of
this entity. Finally, we are in discussions with a small Dutch
combinatorial chemistry company to license a technology platform
that enables us to design new types of therapeutic peptides –
which we call Proteands. We envision Proteands as the next
generation of cancer chemotherapy agents, offering advantages
over current protein therapies, mostly MAbs. Proteands may offer
greater safety and specificity and much-reduced manufacturing
costs. Ultimately, we envision ActiPep as a robust drug
discovery company with a substantial portfolio of disease
targets and drug development collaborations. Our success in
realizing this vision will establish a steady stream of revenue
and profits to reward our shareholders. |
|
|
 |
James V. Adam, CEO
2550 University Ave. West, Suite 341N
St. Paul, MN 55114
651-646-0164
jadam@blizzardgenomics.com
|
|
Blizzard Genomics is an
instrumentation company developing proprietary microarray
instruments, software and consumables for discovery,
characterization and analysis of genes and proteins. Blizzard’s
first product, the I-ScanÔ
Imager, is designed for individual researchers and clinicians
whose needs can no longer be met with expensive, inconveniently
centralized and difficult to use instruments. These researchers
are part of a rapidly emerging group of scientists who
understand the importance microarray techniques bring to their
research, but for a variety of reasons have underutilized their
capabilities. The microarray scanner market is already large
and getting larger. The experts suggest market growth at 44%
annually over the next 5 years growing to $1.6 billion within 4
years.
Blizzard’s I-Scan™ Imager is a revolutionary new design
specifically targeted at the next wave of 48,000 small academic
labs housing about 350,000 researchers. These researchers
currently do not use microarray techniques at all, or access
imaging and analysis instrumentation from a central or contract
core facility. As experimentation into new fields of use
expands, these researchers will require an on-site, lower cost,
more reliable imaging method – I-Scan. Blizzard expects to
commercially introduce I-Scan through a distributor network in
the third quarter of this year. To support the launch, Blizzard
is raising $2 million in a private placement, Preferred A
financing. |
|
|
 |
Kevin L. Nickels, CEO
6570 Edenvale Boulevard
Eden Prairie, MN 55346
952-974-0490
knickels@celleration.com
|
|
Celleration™,
Inc. is a proprietary ultrasound based development stage medical
device company that is clinically validating a novel therapeutic
treatment of chronic wounds by proactively conducting a large
pivotal clinical trial. Celleration’s core technology is
a patented non-imaging, non-contact ultrasound system called
Mist Therapy System (“MIST™”). The Company has demonstrated the
technology’s ability to accelerate the healing of chronic wounds
through stimulating healthy cells during all three phases of the
healing process, including management of bacteria. Due to these
mechanisms of action, the Company believes that a broader market
application for the technology exists beyond chronic wound
management. |
|
|
 |
Jon Brodd, CEO
2045 Wooddale Drive
Woodbury, MN 55125
651-251-1451
jbrodd@cimananotech.com
|
|
Cima NanoTech, Inc. is an early
growth advanced materials company specializing in the
development and commercialization of nano-metal based products
for use in electronics and biotechnology applications.
Headquartered in St. Paul, MN, Cima's researchers have developed
two different patent-protected processes that produce a wide
range of nanometals and metal alloys. These nanometals and metal
alloys form the innovative technology platform which serves as a
basis for Cima's product development. |
|
|
Winners of the UofM Business Plan
Competition |
Paul Sustman, CEO
1200 Main Street
Hopkins, MN 55343
952-933-2331
pas@constantdata.com |
|
Constant Data
delivers scalable, high availability storage management
software focused on enterprise
data protection and distribution. We develop real-time hybrid
data replication and failover solutions for
heterogeneous server and operating environments. |
|
|
 |
Steven J. Healy, CEO
9600 West 76 Street, Suite T
Eden Prairie, MN 55344
952-345-2961
shealy@discdyn.com |
|
Disc
Dynamics, Inc. (DDI), founded in August 2000, is a
privately held orthopedic spine company based in Minnesota. The
mission of DDI is to address the unmet clinical needs of back
pain patients and their surgeons by developing and marketing
innovative, standard-setting, high-value, minimally invasive
devices for the safe and effective restoration of spine function
and a measurably improved quality of life. |
|
|
 |
John Haaland, Ph.D., CEO
614 McKinley Place NE
Minneapolis, MN 55413
612-656-4484
johnh@discoverygenomics.net
|
|
Discovery Genomics
discovers what genes do and delivers them for therapy. We
generate revenues from contracts, licenses and product sales.
We provide products for safe, long-lasting gene therapy and
discover therapeutics and drug targets. Our primary interest is
diseases related to blood vessel integrity. We have discovered
and filed patents for six potential drug targets and
therapeutics in this field. We offer services to pharmaceutical
and biotech companies in areas outside of our focus. Our
proprietary Morphant® Technology is the foundation of our
discovery work. Our Sleeping Beauty Transposon™ System is our
delivery platform for human gene therapy. |
|
|
 |
Erich C. Steinbergs, VP
1650 West 82nd Street
Minneapolis, MN 55431
952-884-7337
|
|
EnviroScrub
Technologies Corporation licenses a
commercially-ready multi-pollutant control technology that
cleans or "scrubs" the emissions of fossil fuel-fired power
plants and other industrial facilities. Our technology removes
almost 100% of the gaseous oxides of sulfur (SOx) and nitrogen (NOx)
that create acid rain and smog and contribute to ground-level
ozone. Our process also removes 60-70% of vapor phase mercury
(Hg) and over 99% of particulate Hg. EnviroScrub has a
"tail-pipe" or post-combustion technology that provides a
solution for all fossil-fuel/carbon-based power generation
(e.g., coal, natural gas, fuel oil, biomass, waste-to-energy).
In fact, the technology can be applied to any industrial process
that generates gaseous emissions of SOx, NOx, or Hg (e.g., power
generation plants, oil refineries, pet coke plants, met coke
plants, pulp & paper mills, steel mills, metals smelters).
Our technology is much more effective than wet Flue Gas
Desulfurization (FGD) and Selective Catalytic Reduction (SCR).
Our technology costs substantially less to own and operate than
wet FGD and SCR. Our technology uses a proprietary mineral
sorbent to capture the pollutants. The sorbent is regenerable
on-site without loss or degradation, meaning that it can be used
repeatedly. The sorbent is not a consumable, therefore
eliminating the disposal problems associated with FGD. All
of the sulfur and nitrogen captured by our process is
transformed into useful industrial chemicals and fertilizers.
When our process is applied to coal-fired or waste-to-energy
plants, there is a small waste stream of mercury, which can
easily be contained and safely stored. EnviroScrub has
filed more than 40 US patent applications. The US Patent
Office has sent to EnviroScrub two Notices of Allowances,
accepting a combined total of 105 claims from our first two
patent applications. EnviroScrub is looking for $10-15 million
to complete a commercial-scale unit, which can be operational
in early 2004. |
|
|
 |
Mark J. Rice, MD, President
1509 Bull Lea Drive, Suite 300
Lexington, KY 40511
859-255-2606 x222
MarkBRM@aol.com
|
|
Fovioptics,
based in Lexington, Kentucky, is developing the Retinal Blood
Analyzer (RBA), a non-invasive blood diagnostic system. The RBA
uses the Company’s patent-protected data analysis processes,
combined with existing retinal camera technology, to measure
important blood components and other critical care metrics using
the human body’s natural window to the blood: the eye. This
breakthrough technology platform solves the inherent problems
that have plagued competing non-invasive diagnostic efforts and
offers significant advantages over traditional needle-based
systems, including cost, patient comfort, repeatability, and
infection control. The RBA has the potential to provide
immediate, real-time measurements for a variety of applications
previously attainable only through blood sampling or other
invasive means, including:
·
Glucose (diabetes)
·
Hemoglobin (anemia)
·
Bilirubin (infant
jaundice)
·
Intracranial pressure
(ICP) (head trauma)
Fovioptics presents a unique venture
capital opportunity in the medical diagnotic arena: a broad,
proprietary technology platform, large and diverse market
opportunities, strong initial clinical data, and an experienced
development team. |
|
|
 |
Stephen C.
Roberts, M.D., CEO
1650 West 82nd Street, Suite 1040
Bloomington, Minnesota 55431
952-881-4105
sroberts@gelstat.com
|
|
Migraine is a severe and
debilitating disease affecting 28 million Americans and costing
the U.S. economy over $20 billion annually in direct medical
expenses and lost productivity.
GelStat Corp. has developed a non-prescription
product, “GelStat Migraine” that relieves migraine headaches
without side effects. Clinical trials demonstrate the efficacy
and safety of this product, which will soon be launched at
retail nationwide. Company founders have extensive experience in
new product introductions, having previously brought to market
products such as “Cold-Eeze”, which attained retail sales of
$140 million within 18 months of launch. Furthermore, the
Company intends to leverage the unique delivery system of
GelStat Migraine to develop a broad line of effective OTC
products. “GelStat Sleep”, for the treatment of insomnia, is
the Company’s other initial product. This product, which will
also be launched at retail within several months, addresses the
needs of 70 million Americans with occasional insomnia. Thus
both GelStat Migraine and GelStat Sleep are unique, effective,
high margin products addressing multi-billion dollar markets.
Their anticipated success will allow the Company first to
establish and then to expand its foothold in the lucrative and
growing OTC health market. |
|
|
 |
Ron Schmitz, CEO
2119 Viburnum Trail
Eagan, MN 55122
612-819-7273
schmitz67@msn.com
|
|
Grand Avenue Software is a start-up
helping medical products companies reduce costs and shorten
their time-to-market through a collaborative suite of compliance
and quality management solutions. The company's collaborative
compliance solutions turn customer's information, data and
processes into business intelligence. The result: enhanced
regulatory compliance with improved business process efficiency. |
|
|
 |
Byron Gilman, CEO
6466 City West Parkway
Eden Prarie, MN 55344
952-943-1683
bgilman@harbingermedical.com |
|
Harbinger Medical markets a non-invasive cardiac
diagnostic tool that helps physicians more accurately assess a
patient's risk of life threatening arrhythmias. Harbinger aids
the physician's decision regarding treatment options, which
range from lifestyle changes to anti-arrhythmic medication to
the implantation of a defibrillator. Their first target market
includes 350,000 people each year who suffer a heart attack.
This market represents a potential of over 1 million diagnoses a
year. Additional uses now being studied include periodic
monitoring of CHF and heart attack patients that can increase
the potential diagnoses per year to over 9 million a year.
Harbinger has developed, patented and obtained FDA approval of
this new analytic tool, with a total investment of $2 million
dollars. Over the last nine years the company has fine tuned the
technique and tested it on over 300 patients in collaboration
with leading cardiologists in the US and Europe. The Harbinger
product fills a void in the diagnostic pathway a patient travels
on their way to a determination of appropriate treatment. Today,
cardiac treatment for the post-heart attack patient is a $1
billion market. Harbinger has put itself in the position to
beneficially impact over 1 million diagnoses a year. |
|
|
 |
Wally Danielson, CEO
5251 W. 73rd Street, Suite J
Edina, MN 55439
952-842-9322
wally@impresmed.com
|
|
Impres
Medical is developing a new treatment called Elate™
to address a large unmet clinical need in gynecology. Over 16
million women in the US alone have abnormal uterine bleeding (AUB),
and have few effective treatment alternatives other than major
surgery. Elate™ is a catheter delivered technology that can
easily be performed in the physician’s office, and uses a new
mechanism of action discovered by Impres called Deactivation.
Elate™, which is being designed to completely stop monthly
bleeding, should be a well reimbursed first line therapy
alternative to hysterectomy. The Company has completed a 20
patient human trial confirming proof of concept for the Elate™
procedure. Impres Medical has captured a strong IP position,
attracted an experienced management team, recruited a talented
and active Board, and developed an impressive investor base.
The Company has successful completed a $2.3 million Series A
financing and is beginning an $8-10 million Series B raise. |
|
|
 |
Ken Rosenblum, CEO
5620 Smetana Drive, Suite 300
Minnetonka, MN 55343
952-548-94000 ext. 202
krosenblum@instymeds.com
|
|
Mendota Healthcare, an early
revenue stage company, is the creator of the
InstyMeds prescription
dispensing system, the first ATM-like dispenser of prescription
medications. The InstyMeds system addresses the need of
hospital pharmacists to dispense 24 hours/day, 7 days/week.
InstyMeds dispensing will decrease hospital staffing costs,
minimize dispensing errors, apply barcode technology to
outpatient dispensing and decrease patient waiting time for
prescriptions. While Mendota is marketing first to hospital
ER’s, the InstyMeds technology will also be useful to the 55,000
US retail pharmacies. InstyMeds systems can reduce pharmacy
costs and increase in-store foot traffic by offering convenient,
round the clock prescription services. |
|
|
 |
Gary Doan,
CEO
5666 Lincoln Drive, #205
Edina, MN 55436
952-936-7733
gdoan@intradyn.com
|
|
IntraDyn™
Inc. is a startup company that has completed product
development, testing and customer trials. IntraDyn™ is currently
preparing to launch it's first product in May 2003. More
information will be available then at the company's web site (
www.intradyn.com ). |
|
|
 |
Bill Drake, CEO
1853 Buerkle Road
St. Paul, MN 55110
651-779-6859 x110
bdrake@islet.com
|
|
Islet
Technology is a cell therapy company initially
focused on diabetes. Our mission is to make islet
transplantation - a breakthrough cure - a reality for millions
of people with diabetes. Positioned to be the leading supplier
of insulin-producing islets for transplantation, Islet
Technology has innovative and proprietary isolation and
microencapsulation technologies used in the processing of
islets. Building on these technologies, we have designed a
two-phase business strategy: 1) establish U.S and European
islet cell-processing facilities to supply islets to
transplant centers worldwide ($1 billion annual revenue), and 2)
add Islet Technology's proprietary microencapsulation technology
to the cell processing ($30 billion annual revenue), eliminating
the need for expensive and often risky anti-rejection drugs that
are otherwise required for life with an islet transplant. |
|
|
 |
Toby Dayton,
COO/CFO
4301 Highway 7, Suite 155
St. Louis Park, MN 55416
952.929.5627
toby@linkup.com |
|
JobDig
is an employment related media company that helps businesses of
all sizes more effectively and efficiently meet their hiring and
recruiting needs. We do this through classified advertising and
integrated, multimedia solutions involving print, the web,
radio, and television. We publish a weekly employment newspaper
titled 'JobDig' as well as an online jobs website 'JobDig.com.’
In addition, we deliver radio-powered classifieds, and are
producing programming for television and radio. We currently
serve the upper Midwest with unique publications in 6 markets
that will grow to 10 by year-end. The highly scalable business
model benefits from very low 'per-market' overhead through the
centralization of both our telemarketing sales force and
production. The 5-year plan projects a total U.S. coverage of
over 65 individual markets and revenue of $86 million. The
company’s CEO, G.L. Hoffman, possesses a very successful
entrepreneurial track record having founded and grown two
companies, Varitronic Systems and Insignia Systems (NASDAQ:ISIG),
that both went public. We are currently raising our third round
of financing, of which more than half has been raised to date.
|
|
|
Modular Computing & Communications |
John Colby,
CEO
2141 Kenwood Drive East
Maplewood, MN 55117
651-776-3565
jecolby@thecolbygroup.com
|
|
Modular
Computing & Communication (MC2), a Delaware
corporation, was formed to develop and market a computing and
communications solution for the non desk-bound user. The
company’s first product offering will provide a true advance in
portability and wireless connectivity. This will be accomplished
through a unique combination of technologies previously
developed by IBM, Intel, and Siemens with additional technology
being developed by MC2. The main component of MC2's technology
design is known as "PAC"TM (Personal
Access Comm or Phone
And Computer). Packaged with
wireless voice and data services, MC2's "my-PAC"TM
phone/computer system will provide users the functionality of a
cell phone, the power of a laptop, and the convenience of a PDA,
all in one compact device that they can carry effortlessly on
their hips. The company will also offer 1) wireless network
design and implementation services and 2) voice and data carrier
services. |
|
|
 |
Jerry Mattys, CEO
539 East Lake Street
Wayzata, MN 55391
952-475-8094
jmattys@medisyntech.com
|
|
Medisyn
Technologies, Inc. is
a drug design and optimization company focusing on the discovery
and pre-qualification of novel drug candidates (leads.) Over
the past 20 years, the underlying technology of Medisyn has
identified 120 lead candidates in 30 different therapeutic
classes with in vivo validation for five different
therapeutic classes including cancer. Medisyn is initially
focusing on identifying effective cancer therapies and has 26
patent pending cancer compounds for license to pharmaceutical
and biotechnology partners. Medisyn's proprietary Forward
Engineering™
in silico prediction platform is capable of designing new
or improved molecules from pre-specified properties. The
technology can identify molecules that meet the desired
properties and accurately assess their drug safety, efficacy,
ADME/Tox , potency, and mechanism of action in novel
compounds. Medisyn's unique methodology and these supporting
data have been published in over 100 peer review articles.
Medisyn can solve drug discovery problems for its customers by
providing pre-qualified lead candidates for them to take through
clinical trials and by providing information to its partners to
aid in their decision making on which drugs to invest in. The
company is looking for financing partners to realize its vision. |
|
|
 |
Kevin Sundquist, CEO
4802 Park Glen Rd.
St
Louis Park, MN 55416
612.386.3119
kevin@mrinstruments.com
|
|
MR Instruments
is improving the quality of people's lives and reducing the cost
of medical care through the commercialization of new magnetic
resonance imaging products. These products are from an
innovative, patented technology developed over 14 years at 3
major universities by world-class scientists and financially
supported by the National Institute of Health. In the first
year, because of an experienced and focused management team, the
company has implemented growth strategies that created revenue,
attracted top talent and quickly moved to commercialize the
first two products. |
|
|
 |
Lenny
Engelhardt, VP, Business Development
12 Eliyahu Hakim Street
Tel Aviv, Israel 69120
011-972-55-330046
lenny@optinetix.com
|
|
Optinetix's
optical TV messaging utilizes conventional TV advertising to
distribute product promotions. Encoded coupon information is
broadcast with the TV advertisement and optically captured and
decoded by an inexpensive device to create and print a coupon.
The consumers may subsequently use the printed coupon for
shopping at a retailer. No modifications are required to the
existing TV sets or broadcast infrastructure. Optinetix's TV
coupons offer viewers a direct cash incentive to watch a TV
commercial. There is no mass communication channel available to
deliver tangible incentives via TV in general or specifically
via commercials. Optinetix's technology enables an improved
delivery platform for a large well-established industry.
Advertisers spend millions promoting their products in TV ads
while viewers often disregard the content, change channels or
leave the room during the advertising breaks in the programs.
There is no incentive for the viewer to watch a TV ad other than
an info add-on to the scheduled programming. The company's
technology combines electro-optic detection with advanced
digital signal processing and supports data acquisition embedded
in the visual portion of a video signal at a relatively high
baud rate. The company filed for two patents that cover both the
core technology and the associated applications. Optinetix Inc.
founded in August 2000, registered in the US (Delaware) with an
R&D subsidiary in Israel. |
|
|
 |
Paul Sullivan, CEO
1125 Nathan Lane North
Plymouth, MN 55441
763-545-8849
psullivan@pumpworks-inc.com
|
|
PumpWorks
engineers and manufactures
high-technology pumps. Success has been demonstrated based
on our patent protected technology by recent market acceptance
and our first profitable year. Revenues in 2002 were $2.5M up
from $0.2M the previous year. A majority of revenue is
from leaders in their field such as SEARS and MAYTAG. Our
forecasts indicate growing revenues reaching $87M in 2007.
Our competitive
advantage is based on the extremely simple design consisting of
a single moving part in a pump/motor combination offering a
unique set of capabilities found in no other pump. Our high
quality pumps can handle both liquid and vapor simultaneously
without harm to the pump. The pumps are real-time controllable
for precise dosing on demand, highly durable/reliable,
hermetically sealed, and small in size compared to similar
performing pumps. Our pumps are physically scalable from
the size of
a coffee cup down to the size of the tip of a pencil. The
pump, utilizing identical technology, is ideal for multiple
industries and applications where a unique set of requirement
characteristics are needed in a single small system. For
example, organizations such as GM and NASA have our pumps in
evaluation for fuel cell applications. The medical industry has
also expressed interest and purchased our pumps.
|
|
|
 |
Lawrence B. Schook, Ph.D.,
CEO
2201 W. Campbell Park Drive
Chicago, Il. 60612
312-455-0602
schook@pyxisgenomics.com
|
|
Pyxis
Genomics Inc. is a genomics-based company engaged in
the discovery, development and commercialization of products and
solutions that enhance animal health and performance. Pyxis
Genomics will develop novel products in three sectors of the
agribusiness and health industries. First are customer specific
DNA-based assays for tracking animals and products from farm to
fork. Second is proprietary expression profiling platforms for
genetic management of health and production systems. The third
area will be the identification of gene targets for nutritional
intervention (non-antibiotic feed supplements for livestock and
nutraceuticals for pets). This will include development of
proprietary novel nutrients and enhancers of health as well as
traditional feed supplements. |
|
|
 |
Michael Peterson, CEO
|
|
ShopCloseBuy
is changing the way small businesses win new customers. Our
method and tools
enable restaurants, retailers and service providers to reach out
to those people who are most likely to be converted into new
regular customers—people who already live, work and shop
in their neighborhood.
By putting
a new twist on the most effective marketing techniques, ShopCloseBuy delivers
an easy, effective and inexpensive
solution to the most common problem small businesses face - how
to attract, acquire and retain new customers. We couple
the effectiveness of permission-based marketing with the
cost-efficiency of email. Then we employ geo-targeting to
leverage the strength of the existing base of consumers in the community.
Finally, we wrap it in a 100% managed service model so that it
takes no time or effort. The result is more foot traffic to
individual shops. |
|
|
 |
Bob
Donaldson, CEO
287 6th Street East
St. Paul, MN 55101
612-805-7457
rdonaldson@synchrono.com |
|
Synchrono,
Inc. is a Supply Chain
Management (SCM) software company that has developed the first
real-time 2nd generation SCM planning and execution
technology. Synchrono is targeting the growing SCM market that
AMR Research predicts will increase from
$6.4 billion in 2002 to $13.6 billion
by 2006 with a 19% annual growth rate. Over the last
decade, major software companies such as i2, Manugistics, SAP,
Oracle and Peoplesoft have developed 1st generation
SCM solutions based on batch oriented, mathematical models
embedded in procedurally rooted technology platforms. These
current solutions have come under severe criticism due to
overwhelming complexity, long costly implementations, and less
than promised improvements. Synchrono, Inc. is heralding the
arrival of the first real-time 2nd generation SCM
solution that provides seamless real-time planning and execution
capabilities, designed for rapid implementation, and continuous
plant improvement. Synchrono will be the driving force behind
the “Next Big Event” in the SCM industry by breaking the old
paradigm and driving the new 2nd generation with
proven reductions in order-lead times of 25% - 50% and
reductions of inventories of 20% - 40%. With over 20 plants
sold, 4 in Q1 2003, and 13 implemented in less than 90 days
each, Synchrono is poised for rapid growth through expanded and
improved sales and marketing capabilities. |
|
|
 |
Andrew
Hunkins, CEO
430 First Avenue North,
Suite 790
Minneapolis, MN 55401
612-204-3605
ahunkins@unimax.com |
|
Unimax
provides a
management software framework to keep diverse corporate
databases in sync. Our award-winning solution, 2nd Nature, is
used to uniformly manage communication systems and enterprise
databases at over 7,000 customer locations worldwide. Unimax
also counts many of the largest global communications
manufacturers as strategic partners, including Cisco, Avaya,
Nortel, EADS Telecom - North America (formerly Intecom), and
Philips Business Communications Systems |
|
| © Copyright 2001-2003 by
NetSuds.com, Inc. |
|
